The Ohio Supreme Court recently ruled in the case of Perrigo Sales Corp. v. Harris, affirming a decision that affects how the state taxes prescription drug sales. The court determined that the commercial-activity tax (CAT) should be calculated based on the actual amounts received by Perrigo from its distributors, rather than the higher list prices stated on invoices. This ruling is significant for Perrigo and similar companies, as it clarifies tax obligations in the pharmaceutical industry.
Perrigo Sales Corporation, a manufacturer of generic drugs, sells its products to wholesale distributors, who then sell them to retailers. The crux of the dispute arose from Perrigo's billing practices, where it invoiced distributors at a list price that was often higher than the price negotiated with retailers. The Ohio Department of Taxation, after an audit, claimed that Perrigo should be taxed on the list price, leading to the appeal that was ultimately decided by the state's highest court.
The case began when the Ohio Department of Taxation conducted a commercial-activity tax audit of Perrigo's sales from January 1, 2016, to December 31, 2018. The department asserted that Perrigo had underreported its gross receipts by reporting only the amounts it actually received from distributors, which were lower than the list prices. Perrigo contested this assessment, arguing that the list price did not reflect the actual amount realized from sales.
The Board of Tax Appeals (BTA) sided with Perrigo, stating that the gross receipts should be calculated based on the amounts actually received, minus any chargebacks—adjustments made due to the difference between the list price and the negotiated retailer price. The BTA emphasized that the CAT is a tax on receipts realized by the taxpayer, not on theoretical invoice amounts.
The Ohio Supreme Court, led by Justice Pat DeWine, agreed with the BTA's interpretation. The court stated, "The amount realized is the amount that is received by Perrigo from its distributors in exchange for its prescription drugs." The ruling clarified that Perrigo's gross receipts for tax purposes should be based on the actual payments received from distributors after accounting for chargebacks.
The court's ruling emphasized that Perrigo never received the list price invoiced to distributors. Instead, the actual payment was the negotiated price with retailers, which is the amount that should be considered for tax calculations. This decision aligns with the understanding of gross receipts as defined in the Ohio Tax Code.
The implications of this ruling are significant for Perrigo and potentially for other companies in the pharmaceutical industry. By affirming the BTA's decision, the Ohio Supreme Court has set a precedent that could influence how commercial-activity taxes are calculated for similar businesses. It underscores the importance of actual receipts in determining tax obligations, rather than relying on inflated invoice amounts.
This ruling may lead to changes in how companies report their gross receipts for tax purposes, particularly in industries where chargebacks and negotiated pricing are common. Companies may need to review their billing practices and ensure that they are accurately reflecting the amounts received in their tax calculations.
Looking ahead, it is unclear whether the Ohio Department of Taxation will seek to appeal this decision further. However, the ruling provides clarity for Perrigo and similar businesses regarding their tax obligations under Ohio law. The case highlights the complexities of tax regulations in the pharmaceutical industry and the importance of accurately reporting gross receipts.